(Q51559289)

English

Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.

scientific article published in December 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

0 references

1 reference

based on heuristic

inferred from title

author name string

Pirwany IR

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

Yates RW

2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

Cameron IT

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

Fleming R

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

language of work or name

0 references

publication date

1 December 1999

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

Human Reproduction

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

14

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

12

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

2963-2968

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Insulin resistance in nonobese patients with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Fasting serum insulin in relation to fat distribution, serum lipid profile, and blood pressure in European women: the European Fat Distribution Study.

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

The genetic basis of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Insulin and androgen relationships with abdominal body fat distribution in women with and without hyperandrogenism.

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

The gonadotropic function of insulin

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Which hormone tests for the diagnosis of polycystic ovary syndrome?

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Neuroendocrine control in polycystic ovary-like syndrome

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Inappropriate Secretion of Follicle-Stimulating Hormone and Luteinizing Hormone in Polycystic Ovarian Disease

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2F14.12.2963

21 January 2018

Identifiers

10.1093/HUMREP/14.12.2963

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/10601079

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51559289&oldid=1248223278"